Eli Lilly is set to acquire three small vaccine developers, expanding its work in infectious diseases. This move is expected to give the field a significant boost. In other news, Australia has confirmed its first diphtheria death since 2018, amid the country's worst outbreak in decades. The outbreak has mainly affected remote Indigenous communities, with 245 cases reported this year.

The acquisition by Eli Lilly underscores the importance of vaccine development in combating infectious diseases. Meanwhile, the diphtheria outbreak in Australia highlights the need for vaccination efforts, particularly in vulnerable communities.

• Diphtheria Cases: 245 reported in Australia this year
• Vaccine Expansion: Eli Lilly acquires three small vaccine developers
• UV Protection: Experts stress the importance of protection against high UV levels
• PCOS Name Change: Condition renamed to polyendocrine metabolic ovarian syndrome (PMOS)

"Every exposure to UV, especially every sunburn, increases our risk of skin cancer," says Prof Dorothy Bennett, from St George's, University of London. Jessica Pinel, a nutritionist and the chair of PCOS Jersey, welcomes the name change to PMOS, stating it is "more representative" of the condition as a whole-body issue.

• 170 million: Women globally affected by PCOS/PMOS
• 245: Diphtheria cases in Australia this year
• 2018: Year of the last reported diphtheria death in Australia
• 1991: Year of the last major diphtheria outbreak in Australia

• Who: Eli Lilly, Australian health officials, PCOS Jersey
• What: Vaccine expansion, diphtheria outbreak, PCOS name change
• Impact: Boost to vaccine development, increased awareness of diphtheria and UV protection, improved understanding of PCOS/PMOS

As Eli Lilly expands its vaccine development, Australia continues to combat the diphtheria outbreak, and the medical community embraces the new understanding of PCOS/PMOS, one thing is clear: these developments will have a lasting impact on public health and medical research.